| Literature DB >> 33314745 |
Xianzhi Zhang1, Ryan F Landis1, Puspam Keshri1, Roberto Cao-Milán1, David C Luther1, Sanjana Gopalakrishnan1, Yuanchang Liu1, Rui Huang1, Gengtan Li1,2, Morgane Malassiné1,3, Imad Uddin1,4, Brayan Rondon1, Vincent M Rotello1.
Abstract
Bioorthogonal catalysis provides a promising strategy for imaging and therapeutic applications, providing controlled in situ activation of pro-dyes and prodrugs. In this work, the use of a polymeric scaffold to encapsulate transition metal catalysts (TMCs), generating bioorthogonal "polyzymes," is presented. These polyzymes enhance the stability of TMCs, protecting the catalytic centers from deactivation in biological media. The therapeutic potential of these polyzymes is demonstrated by the transformation of a nontoxic prodrug to an anticancer drug (mitoxantrone), leading to the cancer cell death in vitro.Entities:
Keywords: anticancer therapeutics; bioorthogonal chemistry; nanozymes; polymers
Mesh:
Substances:
Year: 2020 PMID: 33314745 PMCID: PMC7933084 DOI: 10.1002/adhm.202001627
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933